New concept in nutrition for the maintenance of the aging eye redox regulation and therapeutic treatment of cataract disease; Synergism of natural antioxidant imidazole-containing amino acid-based compounds, chaperone, and glutathione boosting agents: A systemic perspective on aging and longevity emerged from studies in humans

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages 373-389

  Babizhayev, Mark A ^a,b  

^a Innovative Vision Products Incorporated   (United States)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

Author keywords

55000 patients' compliance to self administer eye drops; age related ophthalmic diseases; amino acid compounds with synergistic chaperone activity; blindness prevention; cataract; home health care; lens glutathione metabolism; N acetylcarnosine lubricant eye drops; new nutritional concept; nutritional intervention; visual acuity

Indexed keywords

4 HYDROXYNONENAL; 4 OXO 2 NONENAL; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE; ALPHA CRYSTALLIN; ALPHA TOCOPHEROL; AMINO ACID; ANTIOXIDANT; CARNOSINE; CHAPERONE; DEXTRO CARNOSINE; GLUTATHIONE; HEAT SHOCK PROTEIN 90; HISTIDINE; LENS PROTEIN; MALONALDEHYDE; METHIONINE; N ACETYLCARNOSINE; PANTETHINE; PICOLINATE ZINC; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; ZINC DERIVATIVE; IMIDAZOLE; IMIDAZOLE DERIVATIVE;

AGED; AGING; ANTIOXIDANT ACTIVITY; CATARACT; CHELATION; DIET SUPPLEMENTATION; HUMAN; LONGEVITY; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PH; PRIORITY JOURNAL; PROTEIN CARBONYLATION; REGULATORY MECHANISM; REVIEW; VISUAL ACUITY; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY;

AGING; AMINO ACIDS; ANIMALS; ANTIOXIDANTS; CATARACT; DIETARY SUPPLEMENTS; DRUG SYNERGISM; GLUTATHIONE; HUMANS; IMIDAZOLES; MOLECULAR CHAPERONES; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 77955012788     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d6b6c3     Document Type: Review

References (129)

1. Asbell PA, Dualan I, Mindel J, et al. Age-related cataract. Lancet. 2005;365:599-609.
2. Harding JJ. Cataract: Biochemistry, Epidemiology, and Pharmacology. London, United Kingdom: Chapman and Hall; 1991.
3. Brian G, Taylor H. Cataract Blindness-Challenges for the 21st Century. Bull World Health Organ. 2001;79:249-256.
4. Harding JJ. Can drugs or micronutrients prevent cataract? Drugs Aging. 2001;18:473-486.
5. Spector A. Review: oxidative stress and disease. J Ocul Pharmacol Ther. 2000;16:193-201.
6. Brennan LA, Kantorow M. Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. Exp Eye Res. 2009;88:195-203. E-pub June 7, 2008.
7. Maraini G, Williams SL, Sperduto RD, et al. Effects of multivitamin/mineral supplementation on plasma levels of nutrients. Report No. 4 of the Italian-American clinical trial of nutritional supplements and age-related cataract. Ann Ist Super Sanita. 2009;45:119-127.
8. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 2004;160:339-349.
9. Timbo BB, Ross MP, McCarthy PV, et al. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc. 2006;106:1966-1974.
10. Rock CL. Multivitamin-multimineral supplements: who uses them? Am J Clin Nutr. 2007;85:S277-S279.
11. Harrison RA, Holt D, Pattison DJ, et al. Are those in need taking dietary supplements? A survey of 21 923 adults. Br J Nutr. 2004;91:617-623. (Pubitemid 38584786)
12. Schwarzpaul S, Strassburg A, Luhrmann PM, et al. Intake of vitamin and mineral supplements in an elderly german population. Ann Nutr Metab. 2006;50:155-162. E-pub January 9, 2006.
13. Leske MC, Chylack LT, Wu SY, and The Lens Opacities Case-Control Study Group. The Lens Opacities Case- Control Study. Risk factors for cataract. Arch Ophthalmol. 1991;109:244-251.
14. Mares-Perlman JA, Lyle BJ, Klein R, et al. Vitamin supplement use and incident cataracts in a populationbased study. Arch Ophthalmol. 2000;118:1556-1563.
15. Zigler JS Jr. Lens proteins. In: Albert, DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology, Basic Science. Philadelphia, PA: WB Saunders Co; 1994:97-113.
16. Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J. 1995;9:1173-1182.
17. Wannemaker CF, Spector A. Protein synthesis in the core of the calf lens. Exp Eye Res. 1968;7:623-625.
18. Kwan M, Ninikoshi J, Hunt TK. In vivo measurements of oxygen tension in the cornea, aqueous humor and anterior lens of the open eye. Invest Ophthalmol Vis Sci. 1972;11:108-114.
19. Harding JJ, Crabbe MJ. The lens: development, proteins, metabolism and cataract. In: Davson H. ed. The Eye. Vol lB. Orlando, FL: Academic Press; 1984.
20. Halliwell B, Gutteridge JM C. Role of free radicals and catalytic metal ions in human disease: an overview. In: Packer L, Glazer AN, eds. Methods in Enzymology. Vol 186. San Diego, CA: Academic Press; 1990:1-85.
21. Boettner EH, Walter JR. Transmission of the ocular media. Invest Ophthalmol. 1962;1:776-783.
22. Krishna CM, Uppuluri S, Riesz P, et al. A study of the photodynamic efficiencies of some eye lens constituents. Photochem Photobiol. 1991;54:51-58.
23. Dillon J, Spector A, Nakanishi K. Identification of b-carbolines isolated from fluorescent human lens proteins. Nature. 1976;259:422-423.
24. Horwitz J. a-Crystallin can function as a molecular chaperone. Proc Natl Acad Sci U S A. 1992;89:10449-10453.
25. Bloemendal H. The lens proteins. In: Bloemendal H, ed. Molecular and Cellular Biology of the Eye Lens. New York, NY: Wiley;1981:1-47.
26. Attanasio F, Cataldo S, Fisichella S, et al. Protective effects of L- and D-carnosine on alpha-crystallin amyloid fibril formation: implications for cataract disease. Biochemistry. 2009;48:6522-6531.
27. Horwitz J. a-Crystallin. Exp Eye Res. 2003;76:145-153.
28. Harding JJ. Viewing molecular mechanisms of ageing through a lens. Ageing Res Rev. 2002;1:465-479.
29. Derham BK, Harding JJ. Effects of modifications of alpha-crystallin on its chaperone and other properties. Biochem J. 2002;364:711-717.
30. Derham BK, Harding JJ. Effect of aging on the chaperonelike function of human alpha-crystallin assessed by three methods. Biochem J. 1997;328:763-768.
31. van Boekel MA, Hoogakker SE, Harding JJ, et al. The influence of some post-translational modifications on the chaperone-like activity of alpha-crystallin. Ophthalmic Res. 1996;28(Suppl 1):32-38.
32. Cherian M, Abraham EC. Decreased molecular chaperone property of alpha-crystallins due to posttranslational modifications. Biochem Biophys Res Commun. 1995;208: 675-679.
33. Plater ML, Goode D, Crabbe MJ. Ibuprofen protects alpha-crystallin against posttranslational modification by preventing protein cross-linking. Ophthalmic Res. 1997;29:421-428.
34. Ma B. Kasus-Jacobi A. Imidazole-containing peptide-based compounds in sight-threatening age-related eye diseases Expert Rev Ophthalmol 2009 4 581-586
35. Babizhayev MA, Kasus-Jacobi A. Imidazole-containing peptide-based compounds in sight-threatening age-related eye diseases. Expert Rev Ophthalmol. 2009;4:581-586. 35.Wegele H, Müller L, Buchner J. Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol. 2004;151:1-44. E-pub Jan 23, 2004.
36. Muranov KO, Dizhevskaia AK, Boldyrev AA, et al. Search for chaperon-like anticataract drugs, the antiaggregants of lens crystallins. Communication. 1. Chaperonlike activity of N-acetyl carnosine dipeptide: in vitro study on a model of ultraviolet-induced aggregation of betaLcrystallin [in Russian]. Vestn Oftalmol. March-April 2008; 124:3-6.
37. Babizhayev MA. Current ocular drug delivery challenges for N-acetylcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent Pat Drug Deliv Formul. 2009;3:229-265.
38. Babizhayev MA, Micans P, Guiotto A, et al. Nacetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. Am J Ther. 2009;16: 517-533.
39. Mehta AD, Seidler NW. Beta-alanine suppresses heat inactivation of lactate dehydrogenase. J Enzyme Inhib Med Chem. 2005;20:199-203.
40. Severin SE. Problems Concerned With the Biological Activity of Naturally Occurring Imidazole Compounds: Proceedings of Plenary Session Seventh International Biochemical Congress, 1964. New York, NY; 45-61.
41. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. Adv Enzyme Regul. 1990;30:175-194.
42. Lenney JF. Specificity and distribution of mammalian carnosinase. Biochim Biophys Acta. 1976;429:214-219.
43. Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. Clin Chim Acta. 1991;196:193-205.
44. Lenney JF. Separation and characterization of two carnosine-splitting cytosolic dipeptidases from hog kidney (carnosinase and non-specific dipeptidase). Biol Chem Hoppe Seyler. 1990;371:433-440.
45. Kunze N, Kleinkauf H, Bauer K. Characterization of two carnosine-degrading enzymes from rat brain. Partial purification and characterization of a carnosinase and a beta-alanyl-arginine hydrolase. Eur J Biochem. 1986;160: 605-613.
46. Aldini G, Facino RM, Beretta G, et al. Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. Biofactors. 2005;24:77-87.
47. Aldini G, Orioli M, Carini M, et al. Profiling histidinecontaining dipeptides in rat tissues by liquid chromatography/ electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2004;39:1417-1428.
48. Orioli M, Aldini G, Beretta G, et al. LC-ESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827: 109-118.
49. Reddy VP, Garrett MR, Perry G, et al. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ. 2005;2005:pe12.
50. Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett. 2007;581:1067-1070.
51. Babizhayev MA, Deyev AI, Yermakova VN, et al. NAcetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides. 2001;22:979-994.
52. Babizhayev MA, Deyev AI, Yermakova VN, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D. 2002;3:87-103.
53. Babizhayev MA, Deyev AI, Yermakova VN, et al. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther. 2006;1:91-116.
54. Babizhayev MA, Deyev AI, Yermakova VN, et al. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D. 2004;5:125-139.
55. Babizhayev MA. Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO 2004/028536 A1. International Publication. April 8, 2004.
56. Babizhayev MA. Ophthalmic pharmacology of Nacetylcarnosine lubricant eye drops. J Pharmacol Toxicol. 2006;1:201-233.
57. Babizhayev MA. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res. 2004;7:186-198.
58. Babizhayev MA, Yermakova VN, Deyev AI, et al. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti Aging Med. 2000;3:43-62.
59. Yan H, Harding JJ. Carnosine inhibits modifications and decreased molecular chaperone activity of lens alphacrystallin induced by ribose and fructose 6-phosphate. Mol Vis. 2006;12:205-214.
60. McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res. 1994;212:167-175.
61. Gariballa SE, Sinclair AJ. Carnosine: physiological properties and therapeutic potential. Age Ageing. 2000; 29:207-210.
62. Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS Lett. 1995;371: 81-85.
63. Babizhayev MA, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J Drug Target. 2009;17: 36-63.
64. BrownsonC,Hipkiss AR. Carnosine reacts with a glycated protein. Free Radic Biol Med. 2000;28:1564-1570.
65. Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated alpha-crystallin: an in vitro study. Arch Biochem Biophys. 2004;427:110-115.
66. Kang JH, Kim KS, Choi SY, et al. Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu, Zn-superoxide dismutase modification. Biochim Biophys Acta. 2002;1570: 89-96.
67. Yan H, Harding JJ. Carnosine protects against the inactivation of esterase induced by glycation and a steroid. Biochim Biophys Acta. 2005;1741:120-126. E-pub December 8, 2004.
68. Yan H, Harding JJ. Protective effects of carnosine against the inactivation of ezymes induced by glycation and steroid: relevance to cataract. Am J Ophthalmol. 2006; 139(Suppl 3):S55.
69. Hipkiss AR, Preston JE, Himswoth DT, et al. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett. 1997;238:135-138.
70. Babizhayev MA. Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci. 2006;78:2343-2357. E-pub January 4, 2006.
71. Kohen R, Yamamoto Y, Cundy KC, et al. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci U S A. 1988;85:3175-3179.
72. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta. 1989;1004:363-371.
73. Boldyrev AA, Dupin AM, Bunin AYa, et al. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Int. 1987;15:1105-1113.
74. Babizhayev MA, Seguin MC, Gueyne J, et al. L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radicalscavenging and lipid-peroxidase activities. Biochem J. 1994;304:509-516.
75. Pavlov AR, Revina AA, Dupin AM, et al. The mechanism of interaction of carnosine with superoxide radicals in water solutions. Biochim Biophys Acta. 1993;1157: 304-312.
76. Dahl TA, Midden WR, Hartman PE. Some prevalent biomolecules as defenses against singlet oxygen damage. Photochem Photobiol. 1988;47:357-362.
77. Hartman PE, Hartman Z, Ault KT. Scavenging of singlet molecular oxygen by imidazole compounds: high and sustained activities of carboxy terminal histidine dipeptides and exceptional activity of imidazole-4-acetic acid. Photochem Photobiol. 1990;51:59-66.
78. Bate-Smith BC. The buffering of muscle in rigor: protein, phosphate and carnosine. J Physiol. 1938;92:336-343.
79. Babizhayev MA, Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr Clin Pharmacol. 2009;4:4-37.
80. Roberts PR, Black KW, Santamauro JT, et al. Dietary peptides improve wound healing following surgery. Nutrition. 1998;14:266-269.
81. Hipkiss AR, Brownson C. A possible new role for the anti-ageing peptide carnosine. Cell Mol Life Sci. 2000;57: 747-753.
82. Hipkiss AR. Carnosine, a protective, anti-ageing peptide? Int J Biochem Cell Biol. 1998;30:863-868.
83. Zhou S, Decker EA. Ability of carnosine and other skeletal muscle components to quench unsaturated aldehydic lipid oxidation products. J Agric Food Chem. 1999;47:51-55.
84. Aldini G, Carini M, Beretta G, et al. Carnosine is a quencher of 4-hydroxynonenal: through what mechanism of reaction? Biochem Biophys Res Commun. 2002;298: 699-706.
85. Aldini G, Dalle-Donne I, Facino RM, et al. Intervention strategies to inhibit protein carbonylation by lipoxidation- derived reactive carbonyls. Med Res Rev. 2007;27: 817-868.
86. Hipkiss AR, Michaelis J, Syrris P, et al. Carnosine protects proteins against in vitro glycation and cross-linking. Biochem Soc Trans. 1994;22:S399.
87. Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun. 1998;248:28-32.
88. Hipkiss AR, Brownson C, Bertani MF, et al. Reaction of carnosine with aged proteins: another protective process? Ann NYAcad Sci. 2002;59:285-294.
89. Neely MD, Zimmerman L, Picklo MJ, et al. Congeners of N(alpha)-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2-nonenal. Free Radic Biol Med. 2000; 29:1028-1036.
90. Zheng J, Bizzozero OA. Traditional reactive carbonyl scavengers do not prevent the carbonylation of brain proteins induced by acute glutathione depletion. Free Radic Res. E-pub ahead of print.
91. Banjac A, Perisic T, Sato H, et al.The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene. 2008;27:1618-1628. E-pub September 10, 2007.
92. Meister A. Glutathione metabolism. Methods Enzymol. 1995;251:3-7.
93. Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol. 1986;89:1-8.
94. Bannai S, Ishii T. Transport of cystine and cysteine and cell growth in cultured human diploid fibroblasts: effect of glutamate and homocysteate. J Cell Physiol. 1982;112: 265-272.
95. Ishii T, Sugita Y, Bannai S. Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J Cell Physiol. 1987;133:330-336.
96. Murray DL, Rathbun WB. Conditions for maximizing and inhibiting synthesis of glutathione in cultured rat lenses: an application of HPLC with radioisotope detection. Curr Eye Res. 1990;9:55-63.
97. Kinsey VE, Merriam FC. Studies on the crystalline lens. II. Synthesis of glutathione in the normal and cataractous rabbit lens. AMA Arch Ophthalmol. 1950;44:370-380.
98. Rathbun WB, Murray DL. Age-related cysteine uptake as rate-limiting in glutathione synthesis and glutathione half-life in the cultured human lens. Exp Eye Res. 1991;53: 205-212.
99. Xie PY, Kanai A, Nakajima A, et al. Glutathione and glutathione-related enzymes in human cataractous lenses. Ophthalmic Res. 1991;23:133-140.
100. Sadasivudu B, Rao GN, Swamy M. Gamma-glutamyl transpeptidase and gamma-glutamyl cysteine synthetase activity in human lens tissue. IRCS Med Sci. 1981;9:55-56.
101. Rathbun WB, Schmidt AJ, Holleschau AM. Activity loss of glutathione synthesis enzymes associated with human subcapsular cataract. Invest Ophthalmol Vis Sci. 1993;34: 2049-2054.
102. Gander JE, Sethna SS, Rathbun WB. Bovine lens gammaglutamylcysteine synthetase. Inhibition by glutathione and adenine nucleotides. Eur J Biochem. 1983;133: 635-640.
103. Epstein DL, Kinoshita JH. Effect of methyl phenyldiazenecarboxylate (azoester) on lens membrane function. Exp Eye Res. 1970;10:228-236.
104. Epstein DL, Kinoshita JH. The effect of diamide on lens glutathione and lens membrane function. Invest Ophthalmol. 1970;9:629-638.
105. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev. 1998;3:114-127.
106. Atkuri KR, Mantovani JJ, Herzenberg LA, et al. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7:355-359. E-pub Jun 29, 2007.
107. Zhang S, Chai FY, Yan H, et al. Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocininduced diabetic cataract in rats. Mol Vis. 2008;14: 862-870.
108. Seth RK, Kharb S. Protective function of alpha-tocopherol against the process of cataractogenesis in humans. Ann Nutr Metab. 1999;43:286-289.
109. Tamaki N, Funatsuka A, Fujimoto S, et al. The utilization of carnosine in rats fed on a histidine-free diet and its effect on the levels of tissue histidine and carnosine. J Nutr Sci Vitaminol (Tokyo). 1984;30: 541-551.
110. Tamaki N, Ikeda T, Fujimoto S, et al. Carnosine as a histidine source: transport and hydrolysis of exogeneous carnosine by rat intestine. J Nutr Sci Vitaminol (Tokyo). 1985;31:607-618.
111. Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: its properties, functions and potential therapeutic applications. Mol Aspects Med. 1992;13:379-444.
112. Chan WK, Decker EA, Chow CK, et al. Effect of dietary carnosine on plasma and tissue antioxidant concentrations and on lipid oxidation in rat skeletal muscle. Lipids. 1994;29:461-466.
113. Babizhayev MA, Meguro K. Combined use of carnosinase inhibitor with l-carnosines and composition. WO 2004/064866 PCT/JP2004/000351. 2004. Filed January 20, 2003.
114. Dunnett M, Harris RC. High-performance liquid chromatographic determination of imidazole dipeptides, histidine, 1-methylhistidine and 3-methylhistidine in equine and camel muscle and individual muscle fibres. J Chromatogr B Biomed Sci Appl. 1997; 688:47-55.
115. O'Dowd JJ, Robins DJ, Miller DJ. Detection, characterisation, and quantification of carnosine and other histidyl derivatives in cardiac and skeletal muscle. Biochim Biophys Acta. 1988;967:241-249.
116. Babizhayev MA. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev Ind Pharm. 2008;34:1071-1089.
117. Ferraris RP, Diamond J, KwanWW. Dietary regulation of intestinal transport of the dipeptide carnosine. Am J Physiol. 1988;255:G143-G150.
118. Park YJ, Volpe SL, Decker EA. Quantitation of carnosine in humans plasma after dietary consumption of beef. J Agric Food Chem. 2005;53:4736-4739.
119. Gardner ML, Illingworth KM, Kelleher J, et al. Intestinal absorption of the intact peptide carnosine in man, and comparison with intestinal permeability to lactulose. J Physiol. 1991;439:411-422.
120. Gallant S, Semyonova M, Yuneva M. Carnosine as a potential anti-senescence drug. Biochemistry (Mosc). 2000;65:866-868.
121. Hipkiss AR, Brownson C, Carrier MJ. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. Mech Ageing Dev. 2001;122: 1431-1445.
122. Lee YT, Hsu CC, Lin MH, et al. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol. 2005;513:145-150. E-pub April 2, 2005.
123. Stvolinsky SL, Dobrota D. Anti-ischemic activity of carnosine. Biochemistry (Mosc). 2000;65:849-855.
124. Stvolinsky S, Kukley M, Dobrota D, et al. Carnosine protects rats under global ischemia. Brain Res Bull. 2000; 53:445-448.
125. Fujii T, Takaoka M, Tsuruoka N, et al. Dietary supplementation of L-carnosine prevents ischemia/reperfusioninduced renal injury in rats. Biol Pharm Bull. 2005;28: 361-363.
126. Boldyrev AA, Stvolinsky SL, Fedorova TN, et al. Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials [published online ahead of print December 17, 2009]. Rejuvenation Res. doi: 10.1089/rej.2009.0923.
127. Antonini FM, Petruzzi E, Pinzani P, et al. The meat in the diet of aged subjects and the antioxidant effects of carnosine. Arch Gerontol Geriatr Suppl. 2002;8:7-14.
128. Chez MG, Buchanan CP, Aimonovitch MC, et al. Doubleblind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002;17:833-837.
129. Shao L, Li QH, Tan Z. L-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem Biophys Res Commun. 2004;324: 931-936.